Xeljanz approved for rheumatoid arthritis
(HealthDay)—Xeljanz (tofacitinib) has been approved by the U.S. Food and Drug Administration to treat symptoms of rheumatoid arthritis (RA) among people who can't tolerate, or haven't been helped by, the drug methotrexate.
Arthritis & Rheumatism
Nov 07, 2012 |
not rated yet |
0
Pfizer 3Q profit falls 14 pct on generic Lipitor (Update)
(AP)—Drug giant Pfizer Inc. said Thursday that its third-quarter profit fell 14 percent as sales plunged, mainly due to U.S. generic competition to cholesterol fighter Lipitor, long the world's top-selling drug.
Other
Nov 01, 2012 |
not rated yet |
0
Pfizer will buy NextWave Pharma for up to $700M
(AP)—Pfizer said Monday it will buy NextWave Pharmaceuticals Inc., a company that makes a liquid attention deficit hyperactivity disorder drug, in a deal worth as much as $700 million.
Medications
Oct 22, 2012 |
not rated yet |
0
5-question survey may increase COPD diagnoses
A simple, five-question patient-administered survey (COPD-PS) may lead to increased diagnoses of chronic obstructive pulmonary disease (COPD).
Diseases, Conditions, Syndromes
Oct 22, 2012 |
not rated yet |
0
Anti-clot drug recommended for new approval in EU
(AP)—Advisers to European Union regulators have recommended approval of a new anti-clotting drug for use by adults with a common irregular heart rhythm that boosts risk of strokes or blood clots, drugmakers Bristol-Myers ...
Medications
Sep 21, 2012 |
5 / 5 (1) |
0
Studies: Alzheimer drug may stabilize brain plaque (Update)
An experimental drug that failed to stop mental decline in Alzheimer's patients in the U.S. and Canada also showed some potential benefit in slowing brain plaque, fuller results of two major studies show.
Alzheimer's disease & dementia
Sep 11, 2012 |
not rated yet |
0
FDA approves Pfizer drug for rare blood cancer
Pfizer Inc. says the Food and Drug Administration on Tuesday approved its new drug to treat a rare form of blood and bone marrow cancer.
Medications
Sep 04, 2012 |
not rated yet |
0
Pfizer and J&J end development of Alzheimer's drug
Pfizer Inc. and Johnson & Johnson say they are ending development of a once-promising drug designed to treat Alzheimer's disease after the treatment failed in two late-stage clinical trials.
Alzheimer's disease & dementia
Aug 06, 2012 |
not rated yet |
0
Pfizer 2Q net income rises 25 pct on lower costs
Drugmaker Pfizer Inc.'s second-quarter net income jumped 25 percent as sharply lower costs for production, marketing and restructuring more than offset a plunge in revenue from cholesterol fighter Lipitor ...
Other
Jul 31, 2012 |
not rated yet |
0
Alzheimer's drug fails in 1 study, 2nd continues (Update)
(AP) — A closely watched experimental Alzheimer's treatment has failed to slow the disease in one late-stage study, a big disappointment for doctors and patients but not the end of the road for the drug. Pfizer Inc. ...
Alzheimer's disease & dementia
Jul 23, 2012 |
not rated yet |
0
Study reveals how the world's first drug for amyloid disease works
Scientists from The Scripps Research Institute and Pfizer Inc. have published a new study showing how a new drug called tafamidis (Vyndaqel) works. Tafamidis, approved for use in Europe and currently under ...
Medical research
May 29, 2012 |
5 / 5 (3) |
0
|
Pre-nursing home hospitalization of dementia patients incurs sizable Medicare costs
A new study that tracked what Alzheimer's disease and related disorders (ADRD) costs Medicare during three distinct stages of patient care suggests that the government insurer could realize substantial savings ...
Health
Apr 10, 2012 |
not rated yet |
0
Prophylaxis with apixaban feasible for cancer patients
(HealthDay) -- Primary venous thromboembolism prophylaxis with apixaban, an oral direct Factor Xa inhibitor, in ambulatory cancer patients undergoing first- or second-line chemotherapy for advanced or metastatic ...
Cancer
Mar 29, 2012 |
not rated yet |
0
Alzheimer's drug sharply criticized by medical experts
Watching Alzheimer's disease steal away the memory, talents and very selves of its victims is hard enough for the people who love them. But a new pill formulated by a respected pharmaceutical company and approved by the Food ...
Alzheimer's disease & dementia
Mar 23, 2012 |
5 / 5 (1) |
0
FDA panel to weigh second chance for new class of painkillers
(HealthDay) -- A U.S. Food and Drug Administration advisory panel on Monday will weigh the wisdom of allowing new clinical trials of a class of powerful painkillers for osteoarthritis. The drugs may have worked ...
Medications
Mar 12, 2012 |
not rated yet |
0
